MedTrace Logo

Patient Reported Outcomes in Patients With Chronic Migraine Treated With BOTOX®

NCT02502123 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 215

Last updated 2019-04-05

No results posted yet for this study

Summary

This study will prospectively assess long term heath related quality of life in chronic migraine patients currently being treated with OnabotulinumtoxinA for injection (BOTOX®) as standard of care.

Conditions

  • Migraine Disorders

Interventions

OTHER

No Intervention

No intervention was administered in this study.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Goran Davidoic · Allergan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-02
Primary Completion
2019-01-29
Completion
2019-01-29

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02502123 on ClinicalTrials.gov